02/06/2026
Exciting news from the frontiers of male reproductive health! 🚀
Contraline has raised $92.5 million in a Series B to push NES/T Gel toward Phase 3 readiness, regulatory prep, and scaled manufacturing. The goal: a first pharmacologic male contraceptive that preserves testosterone while suppressing s***m production, with a dual-hormonal approach and a growing non-hormonal pipeline (ADAM).
Key takeaway: This funding signals strong investor confidence in expanding men’s reproductive options and accelerating late-stage trials, addressing a major gap beyond condoms and vasectomy. If NES/T hits Phase 3, it could redefine contraception for men and couples worldwide.
Read more: https://ventureburn.com/contraline-raises-92-5m/
💡🧬
Contraline Raises $92.5M to advance NES/T Gel and expand its male reproductive health pipeline and clinical development programmes.